Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Purchases $26,330.00 in Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par bought 1,000 shares of the stock in a transaction on Thursday, October 29th. The shares were acquired at an average cost of $26.33 per share, with a total value of $26,330.00. Following the purchase, the insider owned 6,841,233 shares of the company’s stock, valued at approximately $180,129,664.89. This represents a 0.01% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par bought 9,004 shares of Lycia Therapeutics stock. The stock was bought at an average cost of $26.28 per share, with a total value of $236,625.12.
• On Wednesday, October 28th, Venrock Healthcare Capital Par bought 15,000 shares of Lycia Therapeutics stock. The stock was bought at an average cost of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The stock was bought at an average price of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $18.04 per share, for a total transaction of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par acquired 52,939 shares of Lycia Therapeutics stock. The shares were bought at an average price of $25.91 per share, with a total value of $1,371,649.49.

Lycia Therapeutics Trading Down 4.8%

LYCA stock traded down $1.33 during trading on Friday, reaching $26.40. 202,428 shares of the company were exchanged, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a twelve month low of $22.19 and a twelve month high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.